|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsors and Collaborators: |
Novartis Novartis Vaccines |
| Information provided by: | Novartis |
| ClinicalTrials.gov Identifier: | NCT00433914 |
Purpose
This study is aimed to explore safety and immunogenicity of two formulations of a Meningococcal B Vaccine when administered to healthy infants.
| Condition | Intervention | Phase |
|
Meningococcal Disease |
Biological: Serogroup B meningococcal Vaccine |
Phase II |
| ChemIDplus related topics: | Meningococcal Vaccines |
| Study Type: | Interventional |
| Study Design: | Prevention, Randomized, Single Blind, Uncontrolled, Parallel Assignment, Safety/Efficacy Study |
| Official Title: | A Phase 2, Single Blind, Single Center, Randomized Study of the Safety, Tolerability and Immunogenicity of Two Different Formulations of Novartis Meningococcal B Vaccine, When Administered to Healthy Infants |
| Estimated Enrollment: | 60 |
| Study Start Date: | February 2007 |
| Estimated Study Completion Date: | February 2008 |
Eligibility
| Ages Eligible for Study: | 6 Months to 8 Months |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations
More Information
| Study ID Numbers: | V72P9, Eudract Number: 2006-005589-38 |
| First Received: | February 9, 2007 |
| Last Updated: | August 28, 2007 |
| ClinicalTrials.gov Identifier: | NCT00433914 |
| Health Authority: | United Kingdom: Medicines and Healthcare Products Regulatory Agency |
|
|
|